Park Avenue Securities LLC Sells 539 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Park Avenue Securities LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 26.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 1,480 shares of the biopharmaceutical company's stock after selling 539 shares during the quarter. Park Avenue Securities LLC's holdings in Regeneron Pharmaceuticals were worth $938,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after purchasing an additional 686 shares in the last quarter. Kingsview Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 16.5% in the 4th quarter. Kingsview Wealth Management LLC now owns 1,002 shares of the biopharmaceutical company's stock worth $714,000 after buying an additional 142 shares in the last quarter. Kestra Private Wealth Services LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 12.9% during the fourth quarter. Kestra Private Wealth Services LLC now owns 1,926 shares of the biopharmaceutical company's stock valued at $1,372,000 after acquiring an additional 220 shares during the period. Savant Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 21.2% during the 4th quarter. Savant Capital LLC now owns 985 shares of the biopharmaceutical company's stock valued at $701,000 after purchasing an additional 172 shares during the last quarter. Finally, Essex Financial Services Inc. raised its stake in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. Essex Financial Services Inc. now owns 332 shares of the biopharmaceutical company's stock valued at $237,000 after acquiring an additional 29 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. Citigroup decreased their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a report on Monday, June 2nd. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Finally, Bank of America decreased their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Stock Down 1.2%

Regeneron Pharmaceuticals stock traded down $6.56 on Monday, hitting $522.68. 1,324,809 shares of the stock traded hands, compared to its average volume of 881,135. The business's fifty day simple moving average is $562.50 and its 200 day simple moving average is $646.92. The firm has a market cap of $56.43 billion, a P/E ratio of 13.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the business earned $9.55 EPS. The firm's quarterly revenue was down 3.7% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.